Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy save search
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
Published: 2024-02-21 (Crawled : 23:00) - biospace.com/
CDNA | $8.23 1.98% 70K
|
Health Technology
|
| O: 0.24%
H: 0.85%
C: -0.12%
pipeline solutions therapy
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
Published: 2024-02-21 (Crawled : 19:00) - biospace.com/
LGST | $4.51 -11.31% 13K
|
n/a
| Email alert
Add to watchlist
covid company genetic cell treatment potential therapy study
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
Published: 2024-02-21 (Crawled : 12:00) - prnewswire.com
ARMP | $2.68 5.1% 4.8K
|
Health Technology
|
| O: -0.35%
H: 6.71%
C: 3.18%
presentation pharmaceuticals therapy
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
VYGR | $7.545 -0.07% 98K
|
Health Technology
|
| O: 1.72%
H: 1.82%
C: -1.43%
SGMO | $0.5151 6.18% 340K
|
Health Technology
|
| O: -1.45%
H: 0.74%
C: -13.24%
NBIX M | $132.23 -0.23% 96K
|
Health Technology
|
| O: 0.63%
H: 0.8%
C: -0.37%
disease alzheimer’s research preclinical tau program therapeutics therapy
USD 2.05 billion growth in the Photodynamic Therapy Market from 2022 to 2027, highlighting major innovations and key vendor offerings- Reported by Technavio
Published: 2024-02-16 (Crawled : 13:30) - prnewswire.com
SNGX | $0.405 -6.96% 380K
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: -5.62%
key therapy growth market
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
Published: 2024-02-15 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
potential therapy show
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
Published: 2024-02-14 (Crawled : 21:00) - globenewswire.com
LGST | $4.51 -11.31% 13K
|
n/a
| Email alert
Add to watchlist
nasdaq business cell therapy
Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances
Published: 2024-02-14 (Crawled : 20:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 0.26%
H: 0.87%
C: 0.32%
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: 0.48%
H: 1.56%
C: 1.48%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.75%
H: 0.86%
C: 0.41%
biosimilar report global therapy growth market
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
INKT | $0.8717 3.6K
|
|
| O: 1.33%
H: 6.34%
C: 6.34%
first cancer cell trial therapy
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
INAB | $1.04 -0.95% 110K
|
|
| O: 0.83%
H: 5.79%
C: -7.44%
publication cell immunology therapy glioblastoma
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
RMD | $178.77 0.65% 260K
|
Health Technology
|
| O: -1.57%
H: 1.1%
C: -0.27%
positive therapy
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
BIIB | $191.45 0.49% 310K
|
Health Technology
|
| O: -3.72%
H: 0.58%
C: -3.82%
skyclarys first approval treat therapy
Alexandria Real Estate Equities, Inc. Announces Long-Term Tenant AstraZeneca Is Investing $300 Million in a Next-Generation Cell Therapy Manufacturing Facility at the Alexandria Center for Life Science - Shady Grove Mega Campus in Rockville, Maryland
Published: 2024-02-12 (Crawled : 13:30) - prnewswire.com
ARE A | $117.935 1.22% 110K
|
Finance
|
| O: 0.59%
H: 1.87%
C: 0.91%
life million astrazeneca cell therapy
France CAR-T Cell Therapy Market 2018-2028F - Expansion of Indications Beyond Hematological Malignancies
Published: 2024-02-09 (Crawled : 16:00) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
MO 4 | $41.84 1.31% 2.4M
|
Consumer Non-Durables
|
| O: -0.35%
H: 0.5%
C: 0.4%
beyond cell expansion car-t therapy market
Johnson &Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Published: 2024-02-09 (Crawled : 14:30) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
fda disease granted treatment risk designation therapy
Johnson & Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Published: 2024-02-09 (Crawled : 13:00) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
fda disease granted treatment risk designation therapy
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Published: 2024-02-08 (Crawled : 11:00) - globenewswire.com
BNTX | $87.02 0.99% 140K
|
Health Technology
|
| O: 0.16%
H: 0.17%
C: -1.16%
AUTL | $4.73 -1.46% 99K
|
Health Technology
|
| O: 2.85%
H: 0.0%
C: -7.69%
pipeline cell collaboration car-t therapy
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
DNLI | $16.455 -0.87% 120K
|
Health Technology
|
| O: -0.18%
H: 4.7%
C: 2.11%
expansion therapeutics therapy
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
Published: 2024-02-07 (Crawled : 12:30) - prnewswire.com
COEP | $0.361 2.85% 21K
|
|
| O: -1.59%
H: 5.06%
C: -2.09%
cell treatment program infections therapeutics therapy
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Published: 2024-02-07 (Crawled : 12:00) - globenewswire.com
GSK | $39.685 1.06% 380K
|
Health Technology
|
| O: 0.43%
H: 0.67%
C: 0.21%
ALEC | $5.165 1.47% 51K
|
Health Technology
|
| O: 2.15%
H: 5.51%
C: 3.73%
fda dementia designation grants therapy
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.